News
Zacks Investment Research on MSN1d
Eli Lilly Stock Down 8.2% in a Month: Should You Buy the Dip?Eli Lilly and Company’s LLY shares have lost 8.2% in the past month. A lot of this price decline is due to the global ...
Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...
We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a ...
In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... began the year on the bullish (58%) note, in line with last quarter (59%). Furthermore, the results also ...
Eli Lilly's (LLY) stock surges 14% as its diabetes drug orforglipron meets Phase 3 goals, cutting weight by 8%. Read more ...
In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... of a life sciences division focused on developing a cell therapy for urinary incontinence.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback